NasdaqGM - Nasdaq Real Time Price USD
Tectonic Therapeutic, Inc. (TECX)
20.19
-0.52
(-2.51%)
At close: May 13 at 4:00:01 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -1.3 | -0.84 | -1.39 | -1.09 |
| EPS Actual | -4.34 | -1.2 | -0.84 | -0.93 |
| Difference | -3.04 | -0.36 | 0.55 | 0.16 |
| Surprise % | -232.99% | -42.86% | 39.42% | 14.87% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TECX | -- | -- | -- | -- |
| S&P 500 | 13.17% | 3.05% | 8.05% | 13.75% |
Upgrades & Downgrades
| Initiated | Mizuho: Outperform | 4/21/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/21/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 1/31/2025 |
| Initiated | Raymond James: Outperform | 11/20/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 11/12/2024 |
| Maintains | Leerink Partners: Outperform to Outperform | 11/11/2024 |
Related Tickers
JANX Janux Therapeutics, Inc.
25.33
-2.80%
ITOS iTeos Therapeutics, Inc.
7.85
+13.44%
IDYA IDEAYA Biosciences, Inc.
17.45
-4.90%
KROS Keros Therapeutics, Inc.
13.47
-1.97%
DYN Dyne Therapeutics, Inc.
12.10
-3.66%
MLYS Mineralys Therapeutics, Inc.
15.19
+1.20%
NGNE Neurogene Inc.
15.51
-12.37%
GHRS GH Research PLC
10.06
-0.98%
SYRE Spyre Therapeutics, Inc.
14.75
-1.21%
EWTX Edgewise Therapeutics, Inc.
14.89
+0.47%